ASH 2023 | A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, discusses a pooled analysis which aimed to determine an optimal cut-off point for the Ki-67 index, a prognostic tool in patients with mantle cell lymphoma (MCL). This analysis used data from two datasets – CALGB 50403 (NCT00310037) and an MCL real-world study. In the multivariable analysis, a Ki-67 of greater than 50% was prognostic of progression-free survival (PFS) but not overall survival (OS). Historically, a cut-off of 30% has been used, but Dr Cohen suggests that this should be reconsidered, given these findings. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BMS/Celgene, Novartis, Genentech, BioInvent, Lam Therapeutics, Takeda, AstraZeneca, Loxo/Lilly
Consultancy: ADCT, AstraZeneca, Abbvie, Janssen, BeiGene, Loxo/Lilly
